Australia-based Lumonus, the company behind Lumonus AI, a platform for radiation oncology clinical workflow and automated treatment planning, has announced a collaboration with US-based Memorial Sloan Kettering Cancer Center (MSK), one of the world's premier cancer centres and a leader in radiation therapy treatment planning research.
Through this relationship, Lumonus will license and co-develop MSK's ECHO mathematical optimisation engine into the Lumonus platform and will invest in joint research focused on advancing automated radiation therapy treatment planning.
MSK's ECHO optimisation engine uses constraint-based mathematical methods to compute radiation therapy treatment plans from first principles. Developed over nearly a decade of clinical use and supported by an extensive body of peer-reviewed research, ECHO represents one of the most rigorously validated approaches to automated treatment planning in radiation oncology.
Tim Fox, Chief Product Officer at Lumonus said, "Our strategic collaboration with MSK represents a decisive step forward. The next generation of planning automation requires a mathematically principled solver capable of consistently delivering the optimal plan, working in concert with intelligent review tools that capture the nuanced clinical judgement of physicians in real-world practice. Together with MSK, we are building the infrastructure to move automation from promising results to scaled, routine deployment."
